News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% in the first quarter, selling 113,815 shares and retaining 983,072 shares valued at $46.765 million. Institutional investors collectively own 69.2% of the company, which reported a quarterly loss of $0.94 …
CRISPR Therapeutics (CRSP) stock has seen a significant decline over the past five years but now appears to be fairly valued. Despite promising allogeneic CAR-T programs, its Price-to-Book ratio is in line with the biotech industry average, suggesting investors acknowledge its potential without pricing …
CRISPR Therapeutics AG's Chief Financial Officer, Prasad Raju, reported a bona fide gift of 750 Common Shares on August 7, 2026. This transaction is classified as a disposition, and following the gift, Raju directly holds 14,815 Common Shares. The Form 4 filing indicates the …
This article provides an analyst report from Morningstar on CRISPR Therapeutics AG (CRSP), noting that its gene-editing therapy Casgevy is gaining traction despite initial commercial hurdles. The report highlights the company's focus on CRISPR/Cas9-based therapeutics. It also includes various market data and related analyst …
Quantinno Capital Management LP significantly increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 613.5% in the first quarter, now owning 47,989 shares valued at $2.28 million. Institutional investors hold 69.2% of the company, and analysts maintain a "Moderate Buy" rating with an average …
CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with higher revenue and a reduced net loss, leading to a short-term stock rebound. Despite mixed long-term performance, a discounted cash flow (DCF) model suggests the stock is significantly undervalued at $53.52 compared to a fair …
Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from a "Sell" to a "Hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average target price of $68.06. Despite a recent 3.6% increase in share price, the company reported a quarterly …
This article provides current stock information for Ispire Technology Inc (ISPR), including its stock price, market capitalization, and a note that more news will be available soon. It highlights that the stock closed at $1.710, up 3.01%, as of August 7th. The page is …
Goldman Sachs has reiterated a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $55.00. This follows similar Hold ratings from other analysts like Wells Fargo, though H.C. Wainwright maintained a Buy rating. The company recently reported quarterly revenue of $10.18 …
Dimensional Fund Advisors LP significantly reduced its stake in CRISPR Therapeutics AG by 45.5% in the first quarter, selling 412,889 shares. Following the sale, the firm now owns 494,218 shares valued at $23.49 million. The article also covers recent analyst ratings, insider trading activity, …
CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following its second-quarter 2026 results, which included an increase in revenue to US$10.18 million, a narrowed net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo …
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10m, significantly beating estimates, and a smaller-than-expected statutory loss. Following these results, analysts have substantially increased revenue forecasts for 2026 to US$54.4m and reduced expected losses, anticipating significant growth. Despite these upgrades, the consensus price …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%Ispire Technology Inc (ISPR) has an earnings forecast score of 9.00, ranking 1st in the Food & Tobacco industry. Analysts have a "Strong Buy" rating with an average price target of $6.50, representing a significant upside. The company's expected revenue for the next quarter …
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …
The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration …
This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring items. This …
Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses …
The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.
CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose …
CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent …
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 …
CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year …
CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, …
This article discusses mixed analyst opinions on two healthcare stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK). Crispr Therapeutics received a "Moderate Buy" consensus with an attractive price target upside, while GlaxoSmithKline holds a "Hold" consensus with a modest upside. The report highlights specific …
Search by ticker symbol or company name and select a result to open its chart.